Compare ADMA Biologics Inc (ADMA) vs Consumer Staples Select Sector SPDR Fund (XLP) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Consumer Staples Select Sector SPDR Fund — how do they compare? ADMA Biologics Inc trades at $9.26 (market cap $2.13B), while Consumer Staples Select Sector SPDR Fund trades at $84.72. The key difference: Consumer Staples Select Sector SPDR Fund is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | XLP | |
|---|---|---|
Market Cap | $2.13B | — |
Sector | Health | — |
52-Week High | $20.38 | $90.00 |
52-Week Low | $7.60 | $75.61 |
Enterprise Value | $2.20B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
XLP trades at $84.1, down 1.05% over the past day, with a bullish technical signal from moving averages and neutral oscillators. The ETF holds a 100% buy rating from analysts and offers a 2.6% dividend yield, positioning it as a defensive play in consumer staples. Recent news highlights its role in portfolio diversification amid market volatility, with retail sales strength supporting the sector.
Outlook remains positive given analyst consensus and defensive characteristics, though risks include sector concentration and economic sensitivity. The ETF's low expense ratio and high yield appeal to income-focused investors, but competition from similar funds and macroeconomic pressures warrant monitoring for sustained performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Consumer Staples Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as Consumer Staples companies by the GICS®. It is non-diversified.
Read more on XLP →
